SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Date of report: June 24, 2021
Commission File Number: 001-39387
(Translation of registrants name into English)
19 Stanwell Road
Penarth, Cardiff CF64 2EZ
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F ☐ Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On June 24, 2021, Renalytix plc (the Company) published a press release announcing the change of its name from Renalytix AI plc to Renalytix plc, a copy of which is furnished as Exhibit 99.1 to this Report on Form 6-K.
|99.1||Press release dated June 24, 2021.|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
/s/ James McCullough
|Chief Executive Officer|
Date: June 24, 2021
Renalytix AI plc
(Renalytix or the Company)
Change of name to Renalytix plc
Change of registered office
Change of website
NEW YORK, June 24, 2021 Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) announces it has changed its name to Renalytix plc.
The Board believes that the new name reflects the fact the Group is focused on bioprognosis for kidney health, engineering a solution that successfully enables early-stage, progression risk assessment for patients with kidney disease.
The Company expects that the change of name will take effect on the AIM market of the London Stock Exchange from 8.00 a.m. on 25 June 2021. The Companys TIDM will remain the same as will the ISIN and SEDOL connected with the Companys shares. Shareholders are unaffected by the change of name and existing share certificates should be retained and remain valid. Any new share certificates issued will bear the name Renalytix plc.
The Company has also changed its registered office to Finsgate, 5-7 Cranwood Street, London EC1V 9EE.
The Groups website containing the information required by AIM Rule 26 has changed to: https://renalytix.com/
For further information, please contact:
|Renalytix AI plc||www.renalytix.com|
|James McCullough, CEO||Via Walbrook PR|
|Stifel (Nominated Adviser, Joint Broker)||Tel: 020 7710 7600|
|Alex Price / Nicholas Moore|
|Investec Bank plc (Joint Broker)||Tel: 020 7597 4000|
|Gary Clarence / Daniel Adams|
|Walbrook PR Limited||Tel: 020 7933 8780 or firstname.lastname@example.org|
|Paul McManus / Lianne Cawthorne||Mob: 07980 541 893 / 07584 391 303|
About Kidney Disease
Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, or 37 million people, currently have chronic kidney disease (CKD). Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and one out of two people with very low kidney function who are not on dialysis do not know they have CKD.1 Kidney disease is referred to as a silent killer because it often has no symptoms and can go undetected until a very advanced stage. Each year kidney disease kills more people than breast and prostate cancer. Every day, 13 patients in the United States die while waiting for a kidney transplant.
KidneyIntelX, is a first-of-kind, bioprognosticTM platform that employs a proprietary artificial intelligence-enabled algorithm to combine diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record, or EHR, systems, to generate a unique patient risk score. This patient risk score enables prediction of progressive kidney function decline in chronic kidney disease, or CKD, allowing physicians and healthcare systems to optimize the allocation of treatments and clinical resources to patients at highest risk.
Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Companys lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.